(R)-Thiorphan

(R)-Thiorphan

SCHEMBL7312756

O=C(O)CNC(=O)[C@H](CS)Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MME P08473 6/20 1.00
ACE P12821 3/20 1.00
ALDH1A1 P00352 2/20 1.00
HPGD P15428 1/20 1.00
MAPK1 P28482 1/20 1.00
HSD17B10 Q99714 1/20 1.00
MEN1 O00255 1/20 1.00
MAPT P10636 1/20 1.00
ECE1 P42892 1/20 1.00
BLM P54132 1/20 1.00
NPEPPS P55786 1/20 1.00
KMT2A Q03164 1/20 1.00
CPA3 P15088 1/20 0.62
FOLH1 Q04609 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
(S)-Thiorphan SCHEMBL49662 1.00 MME (1.00) MMEACEALDH1A1HPGDMAPK1
Thiorphan SCHEMBL401174 1.00 MME (1.00) MMEACEALDH1A1HPGDMAPK1
Thiorphan SCHEMBL399227 0.92 MME (0.84) MMEACEALDH1A1HPGDMAPK1
SCHEMBL8861649 0.91 MME (0.83) MMEACEALDH1A1HPGDMAPK1
SCHEMBL10447979 0.90 MME (0.81) MMEACEALDH1A1HPGDMAPK1
Thiorphan SCHEMBL10038977 0.88 MME (0.78) MMEACEALDH1A1HPGDMAPK1
SCHEMBL4442570 0.88 MME (0.78) MMEACEALDH1A1HPGDMAPK1
SCHEMBL10038979 0.88 MME (0.78) MMEACEALDH1A1HPGDMAPK1
SCHEMBL8861684 0.87 MME (0.77) MMEACEALDH1A1HPGDMAPK1
SCHEMBL7103054 0.85 MME (0.74) MMEACEALDH1A1HPGDMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6048852-A BACTERICIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-04-11 US claimed
EP-0900197-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1999-03-10 EP claimed
WO-1997030027-A1 BETA-THIOPROPIONYL-AMINOACID DERIVATIVES AND THEIR USE AS BETA-LACTAMASE INHIBITORS SMITHKLINE BEECHAM PLC (GB) 1997-08-21 WO claimed
US-4513009-A GLYCINE, ALANINE AND SERINE DERIVATIVES SOCIETE CIVILE BIOPROJET (FR) 1985-04-23 US claimed
JP-8176100-A None JP disclosed
US-20220024920-A1 ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF HORIZON ORPHAN LLC (US) 2022-01-27 US disclosed
EP-3316877-B1 ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF HORIZON ORPHAN LLC (US) 2019-10-30 EP disclosed
WO-2017004485-A1 ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF RAPTOR PHARMACEUTICALS INC. (US) 2017-01-05 WO disclosed
EP-0723974-B1 Derivatives of mercaptoalkanoyldipeptides, their preparation and pharmaceutical compositions containing them ADIR (FR) 2001-08-16 EP disclosed
US-6048852-A BACTERICIDES SMITHKLINE BEECHAM P.L.C. (GB) 2000-04-11 US disclosed
US-5801274-A N- mercaptoacyl(amino acid or peptide)! compounds and S-lipophilic aliphatic carbonyl derivatives thereof as antihypertensives INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1998-09-01 US disclosed
EP-0609310-B1 N-(MERCAPTOACYL)AMINO ACIDS, METHODS OF THEIR PREPARATION AND THERAPEUTIC USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM INST NAT SANTE RECH MED (FR) 1998-07-29 EP disclosed
EP-0595878-A1 ACYLMERCAPTOALKANOYLDIPEPTIDES, METHODS OF PREPARATION AND THEIR THERAPEUTIC USE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1994-05-11 EP disclosed
EP-0566157-A1 Neutral metalloendopeptidase inhibitors in the treatment of hypertension SCHERING CORPORATION (US) 1993-10-20 EP disclosed
EP-0539848-A1 N-(mercaptoacyl)amino acids, methods of their preparation and therapeutic use, and pharmaceutical compositions containing them INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1993-05-05 EP disclosed
WO-1993008162-A1 N-(MERCAPTOACYL)AMINO ACIDS, METHODS OF THEIR PREPARATION AND THERAPEUTIC USE, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1993-04-29 WO disclosed
WO-1993002099-A1 ACYLMERCAPTOALKANOYLDIPEPTIDES, METHODS OF PREPARATION AND THEIR THERAPEUTIC USE INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1993-02-04 WO disclosed
EP-0524553-A1 Acylmercaptoalkanoyldipeptides, methods of preparation and their therapeutic use INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1993-01-27 EP disclosed
US-4749688-A Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension SCHERING CORPORATION (US) 1988-06-07 US disclosed
US-4513009-A GLYCINE, ALANINE AND SERINE DERIVATIVES SOCIETE CIVILE BIOPROJET (FR) 1985-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024920-A1 ADO-RESISTANT CYSTEAMINE ANALOGS AND USES THEREOF GLS, CTH, HNMT MME 1078/4885ACE 2223/4885ALDH1A1 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.